550 related articles for article (PubMed ID: 31908301)
1. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
Guckenberger M; Lievens Y; Bouma AB; Collette L; Dekker A; deSouza NM; Dingemans AC; Fournier B; Hurkmans C; Lecouvet FE; Meattini I; Méndez Romero A; Ricardi U; Russell NS; Schanne DH; Scorsetti M; Tombal B; Verellen D; Verfaillie C; Ost P
Lancet Oncol; 2020 Jan; 21(1):e18-e28. PubMed ID: 31908301
[TBL] [Abstract][Full Text] [Related]
2. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
[TBL] [Abstract][Full Text] [Related]
3. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.
Bamias A; Stenzl A; Brown SL; Albiges L; Babjuk M; Birtle A; Briganti A; Burger M; Choudhury A; Colecchia M; De Santis M; Fanti S; Fonteyne V; Gallucci M; Rivas JG; Huddart R; Junker K; Kroeze S; Loriot Y; Merseburger A; Montironi R; Necchi A; Oing C; Oldenburg J; Ost P; Pinkawa M; Ribal MJ; Rouprêt M; Thoeny H; Zilli T; Hoskin P
Eur Urol; 2023 Oct; 84(4):381-389. PubMed ID: 37217391
[TBL] [Abstract][Full Text] [Related]
4. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract][Full Text] [Related]
5. Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
Nevens D; Jongen A; Kindts I; Billiet C; Deseyne P; Joye I; Lievens Y; Guckenberger M
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):587-595. PubMed ID: 35738308
[TBL] [Abstract][Full Text] [Related]
6. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe.
Kroese TE; van Laarhoven HWM; Schoppman SF; Deseyne PRAJ; van Cutsem E; Haustermans K; Nafteux P; Thomas M; Obermannova R; Mortensen HR; Nordsmark M; Pfeiffer P; Elme A; Adenis A; Piessen G; Bruns CJ; Lordick F; Gockel I; Moehler M; Gani C; Liakakos T; Reynolds J; Morganti AG; Rosati R; Castoro C; Cellini F; D'Ugo D; Roviello F; Bencivenga M; de Manzoni G; van Berge Henegouwen MI; Hulshof MCCM; van Dieren J; Vollebergh M; van Sandick JW; Jeene P; Muijs CT; Slingerland M; Voncken FEM; Hartgrink H; Creemers GJ; van der Sangen MJC; Nieuwenhuijzen G; Berbee M; Verheij M; Wijnhoven B; Beerepoot LV; Mohammad NH; Mook S; Ruurda JP; Kolodziejczyk P; Polkowski WP; Wyrwicz L; Alsina M; Pera M; Kanonnikoff TF; Cervantes A; Nilsson M; Monig S; Wagner AD; Guckenberger M; Griffiths EA; Smyth E; Hanna GB; Markar S; Chaudry MA; Hawkins MA; Cheong E; van Hillegersberg R; van Rossum PSN;
Eur J Cancer; 2023 May; 185():28-39. PubMed ID: 36947929
[TBL] [Abstract][Full Text] [Related]
7. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.
Lecouvet FE; Oprea-Lager DE; Liu Y; Ost P; Bidaut L; Collette L; Deroose CM; Goffin K; Herrmann K; Hoekstra OS; Kramer G; Lievens Y; Lopci E; Pasquier D; Petersen LJ; Talbot JN; Zacho H; Tombal B; deSouza NM
Lancet Oncol; 2018 Oct; 19(10):e534-e545. PubMed ID: 30303127
[TBL] [Abstract][Full Text] [Related]
8. Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion.
Hendriks LEL; Dooms C; Berghmans T; Novello S; Levy A; De Ruysscher D; Hasan B; Giaj Levra M; Giaj Levra N; Besse B; Vansteenkiste J; Dingemans AC;
Eur J Cancer; 2019 Dec; 123():28-35. PubMed ID: 31655358
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.
Iyengar P; All S; Berry MF; Boike TP; Bradfield L; Dingemans AC; Feldman J; Gomez DR; Hesketh PJ; Jabbour SK; Jeter M; Josipovic M; Lievens Y; McDonald F; Perez BA; Ricardi U; Ruffini E; De Ruysscher D; Saeed H; Schneider BJ; Senan S; Widder J; Guckenberger M
Pract Radiat Oncol; 2023; 13(5):393-412. PubMed ID: 37294262
[TBL] [Abstract][Full Text] [Related]
10. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium.
Kroeze SGC; Pavic M; Stellamans K; Lievens Y; Becherini C; Scorsetti M; Alongi F; Ricardi U; Jereczek-Fossa BA; Westhoff P; But-Hadzic J; Widder J; Geets X; Bral S; Lambrecht M; Billiet C; Sirak I; Ramella S; Giovanni Battista I; Benavente S; Zapatero A; Romero F; Zilli T; Khanfir K; Hemmatazad H; de Bari B; Klass DN; Adnan S; Peulen H; Salinas Ramos J; Strijbos M; Popat S; Ost P; Guckenberger M
Lancet Oncol; 2023 Mar; 24(3):e121-e132. PubMed ID: 36858728
[TBL] [Abstract][Full Text] [Related]
11. Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology.
Marvaso G; Jereczek-Fossa BA; Zaffaroni M; Vincini MG; Corrao G; Andratschke N; Balagamwala EH; Bedke J; Blanck O; Capitanio U; Correa RJM; De Meerleer G; Franzese C; Gaeta A; Gandini S; Garibaldi C; Gerszten PC; Gillessen S; Grubb WR; Guckenberger M; Hannan R; Jhaveri PM; Josipovic M; Kerkmeijer LGW; Lehrer EJ; Lindskog M; Louie AV; Nguyen QN; Ost P; Palma DA; Procopio G; Rossi M; Staehler M; Tree AC; Tsang YM; Van As N; Zaorsky NG; Zilli T; Pasquier D; Siva S
Lancet Oncol; 2024 May; 25(5):e193-e204. PubMed ID: 38697165
[TBL] [Abstract][Full Text] [Related]
12. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
[TBL] [Abstract][Full Text] [Related]
13. Survival, local control, and health-related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study.
Barzilai O; Versteeg AL; Sahgal A; Rhines LD; Bilsky MH; Sciubba DM; Schuster JM; Weber MH; Pal Varga P; Boriani S; Bettegowda C; Fehlings MG; Yamada Y; Clarke MJ; Arnold PM; Gokaslan ZL; Fisher CG; Laufer I; The Ao Spine Knowledge Forum Tumor
Cancer; 2019 Mar; 125(5):770-778. PubMed ID: 30489634
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
[TBL] [Abstract][Full Text] [Related]
15. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).
Kroese TE; Bronzwaer S; van Rossum PSN; Schoppman SF; Deseyne PRAJ; van Cutsem E; Haustermans K; Nafteux P; Thomas M; Obermannova R; Mortensen HR; Nordsmark M; Pfeiffer P; Elme A; Adenis A; Piessen G; Bruns CJ; Lordick F; Gockel I; Moehler M; Gani C; Liakakos T; Reynolds JV; Morganti AG; Rosati R; Castoro C; Cellini F; D'Ugo D; Roviello F; Bencivenga M; de Manzoni G; van Berge Henegouwen MI; Hulshoff MCCM; van Dieren J; Vollebergh M; van Sandick JW; Jeene P; Muijs C; Slingerland M; Voncken FEM; Hartgrink H; Creemers GJ; van der Sangen MJC; Nieuwenhuijzen GAP; Berbee M; Verheij M; Wijnhoven B; Beerepoot LV; Mohammad NH; Mook S; Ruurda JP; Kolodziejczyk P; Polkowski WP; Wyrwicz L; Alsina M; Tabernero J; Pera M; Kanonnikoff TF; Cervantes A; Nilsson M; Monig S; Wagner AD; Guckenberger M; Griffiths EA; Smyth E; Hanna GB; Markar S; Chaudry MA; Hawkins MA; Cheong E; van Laarhoven HWM; van Hillegersberg R;
Eur J Cancer; 2024 Jun; 204():114062. PubMed ID: 38678762
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
Xuzhang W; Huang H; Yu Y; Shen L; Li Z; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231156387. PubMed ID: 36895853
[TBL] [Abstract][Full Text] [Related]
17. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.
Dhondt B; De Bleser E; Claeys T; Buelens S; Lumen N; Vandesompele J; Beckers A; Fonteyne V; Van der Eecken K; De Bruycker A; Paul J; Gramme P; Ost P
World J Urol; 2019 Dec; 37(12):2557-2564. PubMed ID: 30578441
[TBL] [Abstract][Full Text] [Related]
18. Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups.
Pasquier D; Bidaut L; Oprea-Lager DE; deSouza NM; Krug D; Collette L; Kunz W; Belkacemi Y; Bau MG; Caramella C; De Geus-Oei LF; De Caluwé A; Deroose C; Gheysens O; Herrmann K; Kindts I; Kontos M; Kümmel S; Linderholm B; Lopci E; Meattini I; Smeets A; Kaidar-Person O; Poortmans P; Tsoutsou P; Hajjaji N; Russell N; Senkus E; Talbot JN; Umutlu L; Vandecaveye V; Verhoeff JJC; van Oordt WMH; Zacho HD; Cardoso F; Fournier L; Van Duijnhoven F; Lecouvet FE
Lancet Oncol; 2023 Aug; 24(8):e331-e343. PubMed ID: 37541279
[TBL] [Abstract][Full Text] [Related]
19. Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer.
Kroese TE; van Rossum PSN; Nilsson M; Lordick F; Smyth EC; Rosati R; Nafteux P; D'Ugo D; Chaudry MA; Polkowkski W; Roviello F; Gockel I; Kolodziejczyk P; Haustermans K; Guckenberger M; Nordsmark M; Hawkins MA; Cervantes A; Fleitas T; van Cutsem E; Moehler M; Wagner AD; van Laarhoven HWM; van Hillegersberg R;
Eur J Surg Oncol; 2023 Jan; 49(1):21-28. PubMed ID: 36184420
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
